WASHINGTON/ BEIJING, Aug 28- The chairman of China's Tsinghua Unigroup travelled to the United States this week to meet with board members of Micron Technology and try to revive a politically fraught takeover bid of the U.S. chipmaker, people familiar with the matter said. Senator Charles Schumer of New York called on the inter-agency Committee on Foreign...» Read More
"Ultimately, I don't think lower rates make that much difference anymore," says Dinakar Singh, TPG-Axon Capital CEO, sharing his thoughts on additional Fed easing.
The co-founder of the trailblazing private-equity firm Kohlberg Kravis Roberts is actively involved in managing the firm famous for its leveraged buyout of RJR Nabisco 25 years ago.
CNBC's David Faber reports the latest details on GlaxoSmithKline's takeover bid for Human Genome Science.
Here are five companies that could be bought, according to analyst Ken Hackel of CT Capital, best known for his book, “Security Valuation and Risk Analysis.”
CNBC's Scott Cohn reports on what the Justice Department calls the biggest health care fraud settlement in U.S. history; and CNBC's Seema Mody reports on the details of Bristol-Myers' plans to buy Amylin.
CNBC's Kayla Tausche reports Grupo Modelo has confirmed it is in talks on expanding its relationship with Anheuser-Busch.
CNBC's David Faber speaks to activist investor Carl Icahn regarding how much cash he has available to invest and whether Chesapeake Energy is undervalued.
Human Genome Sciences rejected the $2.6 billion unsolicited takeover bid from GlaxoSmithKline, reports CNBC's Herb Greenberg.
CNBC's Kayla Tausche reports on Illumina playing offense against Roche's hostile takeover bid, and the FMHR crew share their final trades of the hour.
CNBC's David Faber reports the latest details on Illumina's recommendation to shareholders to reject Roche's takeover offer.
Mad Money host Jim Cramer shares his final thoughts on the future of tech giants, Research in Motion and Yahoo.
The Fast Money traders weigh in on how to play unusual options activity in Avon's shares on Monday.
CNBC's Brian Shactman breaks down today's big movers including two downgrades at Stifel Nicolaus, and Avon's rejection of a takeover bid from Coty.
Karen Finerman, Metropolitan Capital Advisors, and Fast Money trader, provides insight on what's next for Illumina, on the heels its recent rejection of Roche's offer.
Cramer ticks off the many winning trades today.
Keith Moore, MKM Partners, discusses how to play Roche's hostile bid for gene sequencer, Illumin, saying ILMN is likely to fight the takeover. Also an update on SanDisk's earnings, with the Fast Money crew.
Fast Money trader Karen Finerman explains what's behind Roche's tender offer for Illumina; and the best way to play the biotech takeout trend.
Is Netflix a possible takeover candidate by Yahoo? Gene Munster, Piper Jaffray, and the Fast Money traders, weigh in on the rumor, and the possible play on the stocks, and options activity. Also a paid to wait options strategy on Yahoo, with Pete Najarian, Fast Money trader.
The Fast Money traders weigh in on possible suitors for RIM, including, Amazon. Also, the play on Jefferies, as shares surge more than 20% on better-than-expected earnings.
Fast Money trader, Karen Finerman takes a closer look at the hostile takeover attempt by Martin Marietta Materials for Vulcan Materials.